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Introduction: The aim was to study the association between 25-hydroxyvitamin D (25(OH)D) levels and the clinical
characteristics of patients with chronic inflammatory rheumatic diseases (CIRD).
Methods: We studied a cross-section from the baseline visit of the CARMA project (CARdiovascular in
rheuMAtology), a 10-year prospective study evaluating the risk of cardiovascular events in rheumatoid arthritis (RA),
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients, and non-CIRD patients who attended rheumatology
outpatient clinics from 67 hospitals in Spain. Non-CIRD group was frequency matched by age with the joint
distribution of the three CIRD groups included in the study. 25(OH)D deficiency was defined if 25(OH)D vitamin
levels were < 20 ng/ml.
Results: 2.234 patients (775 RA, 738 AS and 721 PsA) and 677 non-CIRD subjects were assessed. The median
(p25-p75) 25(OH)D levels were: 20.4 (14.4-29.2) ng/ml in RA, 20.9 (13.1-29.0) in AS, 20.0 (14.0-28.8) in PsA, and 24.8
(18.4-32.6) ng/ml in non-CIRD patients. We detected 25(OH)D deficiency in 40.5 % RA, 39.7 % AS, 40.9 % PsA and
26.7 % non-CIRD controls (p < 0.001). A statistically significant positive association between RA and 25(OH)D
deficiency was found (adjusted (adj.) OR = 1.46; 95 % CI = 1.09-1.96); p = 0.012. This positive association did not reach
statistical significance for AS (adj. OR 1.23; 95 % CI = 0.85-1.80) and PsA (adj. OR 1.32; 95 % CI = 0.94-1.84). When the
parameters of disease activity, severity or functional impairment were assessed, a marginally significant association
between 25(OH)D deficiency and ACPA positivity in RA patients (adj. OR = 1.45; 95 % CI = 0.99-2.12; p = 0.056), and
between 25(OH)D deficiency and BASFI in AS patients (adj. OR = 1.08; 95 % CI = 0.99-1.17); p = 0.07) was also found.
Conclusions: Patients with RA show an increased risk of having 25(OH)D deficiency compared to non-CIRD controls.Introduction
Vitamin D has raised great interest in recent decades
due to its multiple physiological functions, a including
significant role in the regulation of the immune system
[1–7]. Vitamin D deficiency is an extremely common
health problem that affects up to 50 % of the general* Correspondence: miguelaggay@hotmail.com
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stated.population during winter months in the Northern hemi-
sphere [8]. Several studies have pointed out a potential as-
sociation between vitamin D deficiency and cancer, some
chronic infections, cardiovascular mortality and increased
risk of some autoimmune diseases [8–13], such as type I
diabetes mellitus [10], multiple sclerosis [10], systemic
lupus erythematosus (SLE) [9, 11, 12] and rheumatoid
arthritis (RA) [9, 13]. In this regard, some authors have
reported an inverse relationship between serum levels of
25-hydroxyvitamin D (25(OH)D) and disease activity or
functional impairment in patients with RA or early arthritis
[14–21]. In a recent study, vitamin D deficiency was found
in 30 % of RA patients [8]. Most studies assessing serumess This article is distributed under the terms of the Creative Commons
ativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
u give appropriate credit to the original author(s) and the source, provide a link
e if changes were made. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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rheumatic diseases (CIRD) were focused on patients with
RA [9, 13–15, 17–20]. However, fewer studies have ana-
lyzed the presence of 25(OH)D deficiency in other CIRD
such as ankylosing spondylitis (AS) or psoriatic arthritis
(PsA) [21–24].
The aim of this study was to assess 25(OH)D levels in
a cohort of Spanish patients with CIRD that included
patients with RA, AS, PsA and non-CIRD, who were at-
tending rheumatology outpatient clinics, and to deter-
mine the potential relationship between 25(OH)D levels
and clinical characteristics of every disease included in
the group of patients with CIRD.
Methods
Study design
Cross-sectional analysis from the baseline visit of the
project, CARdiovascular in rheuMAtology (CARMA), a
10-year prospective cohort study designed to determine
the cardiovascular mortality risk in patients with CIRD
compared to a cohort of patients without inflammatory
pathological disease [25]. Information on this cohort has
recently been reported. The institutional review board of
each center approved the study and all patients signed
an informed consent agreement.
Patients and controls
Based on the information from the Spanish Society of
Rheumatology (SER), all the Spanish public hospitals
(university and general community hospitals) that have
rheumatology units were invited to take part in the present
study. Finally, 67 (63.2 %) of the 106 centers agreed to par-
ticipate in the study. They recruited 2,986 patients who
attended rheumatology outpatient clinics from July 2010 to
January 2012. Seventy-five patients declined the invitation.
Therefore, 2,911 patients over 18 years old were included
in the study. They were split into two different cohorts ac-
cording to CIRD exposition. The CIRD patients consisted
of 775 patients diagnosed with RA (1987 American College
of Rheumatology (ACR) classification criteria) [26], 738
diagnosed with AS (modified New York criteria) [27]
and 721 patients with PsA (Moll and Wright criteria)
[28]. The control (non-CIRD) group included 677 patients
without inflammatory rheumatic disease. The non-CIRD
group was frequency-matched by age with the joint distri-
bution of the three CIRD groups. Therefore, its distribu-
tion approximates the joint age distribution of the three
CIRD. To see the list of participating centers, we advise
readers to see the Acknowledgements section.
Variables and operative definitions
Both cohorts were evaluated following international proto-
cols including standardized definitions and validated ques-
tionnaires. All patients included were continuously andsystematically evaluated online and, to verify the quality of
the information, an in situ monitoring data assessment
was performed in 15 % of patients randomly selected.
The primary endpoint was the presence of 25(OH)D
deficiency defined as 25(OH)D levels below 20 ng/ml.
The variable sunshine hours per month and province
(geographical area in which the hospital is located) was
established considering the hours of sunlight in the period
of time between 60 and 90 days prior to the visit of inclu-
sion of each patient. For this purpose we used the infor-
mation published by the Spanish Meteorological Agency
(SMA) [29]. When information on sunshine hours of the
month and year was not available, we used the mean value
of sunshine hours of the last 5 years in which information
on sunshine hours in the same period of time and site was
available. The 25(OH)D analysis was locally performed
according to the methodology and reproducibility level
of each institution.
Other variables analyzed were: (1) obesity (BMI ≥30,
kg/m2) and main physical activity during working hours
(low activity: sitting most of the time; moderate activity:
standing most of the time and with little movement or
effort; intense activity: walking most of the time or perform-
ing tasks that require high physical activity); (2) disease
characteristics and parameters of disease activity: rheuma-
toid factor (RF), anti-cyclic citrullinated peptide antibodies
(ACPA), HLA-B27 positivity, erythrocyte sedimentation
rate (ESR) (mm/1st h), ultra-sensitive C-reactive protein
(CRP) (mg/l), disease activity score including 28 joints-
erythrocyte sedimentation rate (DAS28-ESR), health as-
sessment questionnaire (HAQ (0–3)), Bath ankylosing
spondylitis disease activity index (BASDAI (0–10)) and
Bath ankylosing spondylitis functional index (BASFI
(0–10)); (3) sociodemographic variables, and (4) other
factors: disease severity, duration of the disease and
therapies administered including calcium and vitamin D
supplementation.
Statistical analysis
Numerical variables with a normal distribution were
expressed as mean and standard deviation. Variables not
normally distributed were shown as median and interquar-
tile range (IQR, percentile (p)25 − p75). Absolute and rela-
tive frequencies of qualitative variables were calculated.
We performed analysis of the main demographic and clin-
ical variables stratified by type of disease. Stratified analysis
of 25(OH)D deficiency (<20 ng/ml) was performed for
each group of patients according to sociodemographic
characteristics and clinical factors, using the Student t test
or the Mann-Whitney U test. Qualitative variables were
assessed using the Chi-square test, Yates correction, or
Fisher test using 2 × 2 tables.
To study the association between 25(OH)D deficiency
and CIRD, logistic regression models were constructed
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adjusting for potential confounding factors. In this regard,
an adjusted model for sunshine hours was performed. It
was carried out considering for this purpose the period of
time between 60 and 90 days prior to the baseline visit
blood test, which included assessment of 25(OH)D levels.
To reduce variability in the methods of measurement of
25(OH)D from each participating hospital, the mixed
logistic regression models were constructed with robust
variance estimators using the hospital as cluster variable es-
timation. The same procedure was carried out to identify
specific features of each disease. The selection of independ-
ent variables in the multivariate models was based on clin-
ical judgment and those with a p-value <0.20 in the bivariate
analysis. In all models of logistic regression, the independent
variables were adjusted for the other variables in the model.
Data management and statistical analysis were centralized
at the Research Unit of the SER following a pre-established
analysis plan. All the analyses were performed using the
SPSS 21.0 statistical program. Statistical significance
was assumed at p <0.05.
Results
Sociodemographic and clinical characteristics
Demographic and clinical characteristics of patients in-
cluded in this study are summarized in Table 1. There was
a predominance of women in the group with RA, whereas
most AS patients were men. Sex distribution was similar
in the group with PsA. The mean age in patients with RA
was higher than in patients with other CIRD. Although
patients with AS were younger, the duration of disease
was longer than in the other groups. The frequency of
obesity was higher among PsA patients, whereas it was
lower among controls, despite being the group that in-
cluded more sedentary individuals (p <0.001). Smoking
history was more commonly observed in those with AS.
It is worth noting that a great majority of patients with
CIRD included in the study had low disease activity at
time of recruitment. In this regard, CRP and ESR levels
in RA, AS and PsA patients were remarkably low at the
time of inclusion in the study, as well as the functional-
ity scores (HAQ and BASFI, respectively).
Individuals without CIRD (controls) had the following
rheumatic diseases: osteoarthritis (30 %), osteoporosis
(15.2 %), soft tissue disorders (18.8 %) and other non-
inflammatory diseases (36 %). The distribution at recruit-
ment of individuals with CIRD per hospital was uniform
throughout the year 2011, whereas the recruitment of pa-
tients without CIRD occurred mainly between October
and November 2011 (Additional file 1: Table S1).
25(OH)D levels and CIRD
Patients with CIRD had lower 25(OH)D levels than those
from the non-CIRD controls (Table 1). The median(p25 − p75) 25(OH)D levels were: 20.4 (14.4 − 29.2)] ng/ml
in RA, 20.9 (13.1 − 29.00 ng/ml in AS, 20.0 (14.0 − 28.8)
ng/ml in PsA and 24.8 (18.4 − 32.6) ng/ml in non-CIRD
individuals. Globally, 25(OH)D deficiency was detected in
40.5 % of patients with RA, 39.7 % of patients with AS,
40.9 % of patients with PsA and 26.7 % of individuals with
non-CIRD (p <0.001). The median of sunshine hours in
the group of non-CIRD controls was higher than in the
three groups of patients with CIRD (Table 2).
Among the variables related to activity and severity of
inflammatory diseases, ACPA-positive RA patients had a
higher frequency of 25(OH)D deficiency (66.9 %). It was
also the case for AS, with higher values of BASDAI and
BASFI in 25(OH)D-deficient patients (p <0.05 in both
cases) (Table 2).
Multivariate analysis
Multivariate analysis (Table 3) disclosed a positive asso-
ciation with 25(OH)D deficiency in the patients with
CIRD when compared with the non-CIRD subjects. This
association with 25(OH)D deficiency was statistically sig-
nificant in the group of patients with RA (adjusted (adj.)
OR = 1.46; 95 % CI = 1.09, 1.96); p = 0.012. However, the
positive association was not statistically significant for
AS (adj. OR = 1.23; 95 % CI = 0.85, 1.80) and PsA (adj.
OR = 1.32; 95 % CI = 0.94, 1.84). Women with RA had
significantly higher risk of 25(OH)D deficiency than men
(p <0.01). Likewise, obese RA and PsA patients (BMI ≥30)
had higher risk of 25(OH)D deficiency
When the parameters of disease activity, severity or
functional impairment were assessed, a marginally signifi-
cant association between 25(OH)D deficiency and ACPA-
positivity in RA patients (adj. OR = 1.45; 95 % CI = 0.99,
2.12; p = 0.056), and between 25(OH)D deficiency and
BASFI in AS patients (adj. OR = 1.08; 95 % CI = 0.99, 1.17;
p = 0.07) was also found (Table 3).
Discussion
Our results show that Spanish patients with RA attend-
ing rheumatology outpatient clinics have 25(OH)D defi-
ciency. This baseline result is from a cohort of patients
that has been followed prospectively to determine the car-
diovascular outcome. To establish comparisons, we also
assessed baseline 25(OH)D levels in non-CIRD controls
attending the same rheumatology outpatient clinics [25].
Vitamin D plays an important role in the immune regu-
lation [2]. Vitamin D deficiency has been observed in some
autoimmune diseases, in particular in SLE [11, 12, 30] and
RA [8, 20]. However, information related to undifferenti-
ated spondyloarthropathies and AS is limited [21, 22, 31].
It is also the case for PsA [24].
In our series, the frequency of 25(OH)D deficiency
(level <20 ng/ml) was higher in patients with RA than in
the individuals from the non-CIRD control group. The
Table 1 Sociodemographic characteristics, 25(OH)D levels and clinical characteristics of the population included in the study
Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Controls
(n = 775) (n = 738) (n = 721) (n = 677)
Age at inclusion, years, mean (SD) 57.1 (12.3) 48.1 (11.7) 51.8 (12.0) 54.0 (12.4)
Age at the beginning of disease, years, mean (SD) 45.8 (13.4) 29.7 (11.8) 39.5 (13.3) 48.5 (12.4)
Female sex, n (%) 581 (75.0) 200 (27.1) 327 (45.4) 437 (64.5)
Educational level, n (%)
Elementary 467 (60.9) 318 (43.3) 331 (46.3) 229 (34.1)
University /secondary 300 (39.1) 416 (56.7) 383 (53.7) 443 (65.9)
Caucasian Race, n (%) 747 (96.6) 723 (98.0) 712 (98.9) 668 (98.7)
Others 26 (3.4) 15 (2.0) 8 (1.1) 9 (1.3)
Main activity, n (%)
Sedentary 236 (35.0) 263 (39.3) 253 (38.9) 291 (46.3)
Moderate 290 (43.0) 238 (35.5) 241 (37.1) 207 (32.9)
Active with displacement 148 (22.0) 169 (25.2) 156 (24.0) 131 (20.8)
BMI, kg/m2, mean (SD) 26.9 (4.8) 27.4 (4.4) 28.2 (4.7) 26.7 (4.4)
Obesity (BMI ≥30), n (%) 180 (23.2) 186 (25.2) 209 (29.1) 147 (21.8)
Smoking status, n (%)
Current smokers 189 (24.4) 254 (34.4) 157 (21.8) 143 (21.2)
Past smokers 202 (26.1) 240 (32.5) 227 (31.5) 176 (26.0)
Never smokers 384 (49.5) 244 (33.1) 337 (46.7) 357 (52.8)
25 (OH) D
25(OH)D (ng/ml), median (p25 − p75) 20.4 (14.4–29.2) 20.9 (13.1–29.0) 20.0 (14.0–28.8) 24.8 (18.4–32.6)
25(OH)D deficiency, n (%) 314 (40.5) 293 (39.7) 295 (40.9) 181 (26.7)
Sunshine hours/month*, median (p25 − p75) 162 (122–219) 165 (136–233) 178 (128–235) 301 (202–345)
Disease duration, years, median (p25 − p75) 8.0 (3.0–14.0) 15.0 (8.0–26.0) 9.0 (4.0–16.0) 2.0 (0.0–6.0)
RF-positive, n (%) 528 (68.1) – – –
ACPA-positive, n (%) 482 (62.2) – – –
DAS28-ESR, mean (SD) 3.2 (1.2) – 3.0 (1.3) –
HAQ (0–3), median (p25 − p75) 0.5 (0.1–1.1) – 0.4 (0.0–0.9) –
ESR (mm/h), median (p25 − p75) 17.0 (9.0–29.0) 10.0 (6.0–21.0) 12.0 (6.0–21.0) 10.0 (5.0–18)
CRP (mg/l), median (p25 − p75) 3.1 (1.2–8.0) 3.6 (1.6–8.9) 2.9 (1.4–6.1) 1.9 (1.3–3.3)
BASDAI (0–10), median (p25 − p75) – 3.5 (1.7–5.3) – –
BASFI (0–10), median (p25 − p75) – 3.1 (1.3–5.2) – –
HLA-B27, n (%) – 561 (76) – –
Erosions (RA), n (%) 352 (45.4) – – –
Biologic therapy (% ever treated), n (%) 313 (40.4) 349 (47.4) 300 (41.7) –
Vitamin D, n (%) 325 (41.9) 82 (11.1) 114 (15.8) 138 (20.4)
Calcium supplements, n (%) 328 (42.3) 68 (9.2) 105 (14.6) 122 (18.0)
25(OH)D deficiency is defined as 25(OH)D <20 ng/ml. *Hours of sunshine per month considering the period of time between 60 and 90 days prior to the baseline
visit (blood test to determine the levels of 25(OH)D was performed at the baseline visit). BMI body mass index, 25(OH)D 25-hydroxyvitamin D, p25 − p75 25th to
75th percentile, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibodies, DAS28-ESR, disease activity score using 28 joints-erythrocyte sedimentation
rate, HAQ (0–3): health assessment questionnaire, ESR erythrocyte sedimentation rate, CRP C-reactive protein, BASDAI (0–10) Bath ankylosing spondylitis disease
activity index, BASFI (0–10) Bath ankylosing spondylitis functional index, HLA-B27 histocompatibility antigen HLA-B27, RA rheumatoid arthritis
Urruticoechea-Arana et al. Arthritis Research & Therapy  (2015) 17:211 Page 4 of 10present study raises several points of potential interest.
First, the CARMA cohort constitutes the largest series of
comparisons of 25(OH)D levels in three well-established
CIRD. In addition, a cohort of individuals without CIRDwas used for comparison. Second, we assessed patients
who were periodically followed at rheumatology out-
patient clinics. Nevertheless, it is important to emphasize
that baseline levels of 25(OH)D in the control population
Table 2 Bivariate analysis according to each specific entity and the occurrence of 25(OH)D deficiency (25(OH)D <20 ng/ml)






















Female, n (%) 1545
(53.1)









0.079 45.8 (13) 46.1
(13.6)

















0.005 10.1 (8.5) 10.4 (9.1) 0.782 17.6 (11.9) 17.72
(12.1)
0.950 11.2 (8.4) 11.4 (9.3) 0.983 4.4 (6.9) 4.5 (6.2) 0.321
Educational level, n (%)
Elementary 1693
(58.6)
646 (60.4) 819 (56.8) 0.071 212 (68.6) 242 (68.9) 0.926 176 (60.7) 182 (53.8) 0.84 173 (59.5) 200 (59.5) 0.985 85 (47.5) 195 (46.9) 0.891
University/secondary 1194
(41.4)
423 (39.6) 622 (43.2) 97 (31.4) 109 (31.1) 114 (39.3) 156 (46.2) 118 (40.5) 136 (40.5) 94 (52.5) 221 (53.1)
Smoking status, n (%)
Current smokers 743 (25.5) 303 (28.0) 335 (23.2) 83 (24.4) 76 (21.6) 107 (36.5) 113 (33.3) 59 (20.0) 73 (21.6) 54 (30.0) 73 (17.4)
Past smokers 845 (29.0) 332 (30.7) 407 (28.1) 0.001 86 (27.4) 92 (26.1) 0.226 95 (32.4) 107 (31.6) 0.530 101 (34.2) 104 (30.9) 0.650 50 (27.8) 104 (24.8) <0.001
Never smokers 1322
(45.5)
447 (41.3) 705 (48.7) 145 (46.2) 184 (52.3) 91 (31.1) 119 (35.1) 135 (45.8) 160 (47.5) 76 (42.2) 242 (57.8)
Obesity (BMI ≥30), n (%) 2184
(75.0)
327 (30.2) 308 (21.3) 0.001 88 (28.0) 71 (20.2) 0.018 83 (28.3) 75 (22.1) 0.072 102 (34.7) 89 (26.5) 0.025 54 (30.0) 73 (17.5) 0.001
Main physical activity, n (%)
Sedentary 1043
(39.8)
380 (39.3) 553 (40.8) 92 (34.3) 113 (36.1) 103 (39.6) 120 (38.7) 110 (41.5) 119 (39.1) 75 (42.9) 181 (47.6)
Moderate 976 (37.2) 363 (37.5) 472 (36.1) 0.734 113 (42.2) 136 (43.5) 0.669 90 (34.6) 109 (35.2) 0.976 100 (37.7) 107 (35.2) 0.386 60 (34.3) 120 (31.6) 0.576
Active with
displacement
604 (23.0) 225 (23.2) 302 (23.1) 63 (23.5) 64 (20.4) 67 (25.8) 81 (26.1) 55 (20.8) 78 (25.7) 40 (22.9) 79 (20.8)
Sunshine hours /month*,































































RF positive, n (%) - - - - 252 (80.3) 264 (75.0) 0.105 - - - - - - - - -
ACPA positive, n (%) - - - - 210 (66.9) 205 (58.2) 0.022 - - - - - - - - -
Erosions, n (%) - - - - 143 (45.5) 169 (48.0) 0.524 - - - 79 (26.8) 92 (27.3) 0.883 - - -
DAS28-ESR, median
(p25 − p75)























Table 2 Bivariate analysis according to each specific entity and the occurrence of 25(OH)D deficiency (25(OH)D <20 ng/ml) (Continued)
HAQ (0–3), median
(p25 − p75)








0.601 - - -
HLA-B27, n (%) - - - - - - - 218 (74.4) 275 (81.1) 0.042 - - - - -
BASDAI (0–10), median
(p25 − p75)




0.042 - - - - - -
BASFI (0–10), median
(p25 − p75)




0.018 - - - - - -
Treatment
Biologic DMARD, n (%) - - - - 123 (39.2) 150 (42.6) 0.367 145 (49.5) 158 (46.6) 0.470 132 (44.7) 142 (42.1) 0.509 - - -
Vitamin D, n (%) 659 (22.6) 198 (18.3) 392 (27.1) <0.001 120 (38.2) 166 (47.2) 0.020 23 (7.8) 53 (15.6) 0.003 32 (10.8) 68 (20.2) 0.001 23 (12.7) 105 (25.1) <0.001
Calcium supplements,
n (%)
623 (21.4) 191 (17.6) 353 (24.4) <0.001 118 (37.6) 163 (46.3) 0.023 20 (6.8) 42 (12.4) 0.019 33 (11.2) 56 (16.6) 0.050 20 (11.0) 92 (22.0) 0.002
*Hours of sunshine per month considering the period of time between 60 and 90 days prior to the baseline visit (blood test to determine the levels of 25(OH)D was performed at the baseline visit). 25(OH)D 25-
hydroxyvitamin D, BMI body mass index, p25 − p75 25th to 75th percentile, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibodies, DAS28-ESR,
disease activity score using 28 joints-erythrocyte sedimentation rate, HAQ (0–3): health assessment questionnaire, HLA-B27 histocompatibility antigen HLA-B27, BASDAI (0–10) Bath ankylosing spondylitis disease activity















Table 3 Multivariate analysis of 25(OH)D deficiency (25(OH)D levels <20 ng/ml) in patients with chronic inflammatory rheumatic diseases
All Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis
Variables Crude OR Adjusted OR p Crude OR Adjusted OR p Crude OR Adjusted OR p Crude OR Adjusted OR p
(95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
Kind of disease (ref.
controls)
Rheumatoid arthritis 2.07 (1.53, 2.79) 1.46 (1.09, 1.96) 0.012 – – – – – –
Ankylosing spondylitis 2.00 (1.46, 2.74) 1.23 (0.85, 1.80) 0.273 – – – – – –
Psoriatic arthritis 2.03 (1.46, 2.81) 1.32 (0.94, 1.84) 0.110 – – – – – –
Age beginning disease 1.00 (0.99, 1.00) 1.00 (0.99, 1.01) 0.985 1.00 (0.99, 1.01) 0.99 (0.98, 1.01) 0.324 1.00 (0.99, 1.02) 1.00 (0.98, 1.02) 0.715 1.00 (0.99, 1.01) 1.00 (0.98, 1.01) 0.688
Sex (ref. male) 0.86 (0.74, 0.99) 1.06 (0.88, 1.27) 0.561 0.60 (0.43, 0.85) 0.64 (0.42, 0.97) 0.037 1.46 (1.07, 1.99) 1.54 (1.10, 2.17) 0.013 0.82 (0.61, 1.10) 0.95 (0.66, 1.37) 0.781
Disease duration, years 1.01 (1.00, 1.02) 1.00 (0.99, 1.01) 0.894 1.00 (0.98, 1.01) 1.00 (0.98, 1.02) 0.971 1.00 (0.98, 1.01) 1.00 (0.98, 1.02) 0.841 0.998 (0.980, 1.015) 1.00 (0.98, 1.01) 0.581
Educational level (ref.
elementary)
University/secondary 0.86 (0.67, 1.11) 0.99 (0.77, 1.29) 0.963 1.02 (0.71, 1.45) 1.17 (0.69, 1.72) 0.430 0.76 (0.52, 1.10) 0.81 (0.55, 1.19) 0.280 1.00 (0.67, 1.50) 0.94 (0.62, 1.41) 0.765
Smoking status (ref.
current smokers)
Past smokers 0.90 (0.74, 1.10) 0.91 (0.73, 1.13) 0.387 0.86 (0.58, 1.26) 0.80 (0.49, 1.29) 0.354 0.94 (0.62, 1.41) 1.11 (0.72, 1.70) 0.639 1.20 (0.77, 1.88) 1.20 (0.72, 1.99) 0.480
Never smokers 0.70 (0.57, 0.86) 0.73 (0.58, 0.91) 0.005 0.72 (0.51, 1.02) 0.74 (0.50, 1.11) 0.144 0.81 (0.53, 1.22) 0.84 (0.56, 1.26) 0.404 1.04 (0.66, 1.64) 1.12 (0.67, 1.87) 0.662
Obesity (BMI ≥30. kg/m2) 1.60 (1.32, 1.94) 1.96 (1.28, 1.90) <0.001 1.54 (1.09, 2.17) 1.76 (1.18, 2.62) 0.006 1.39 (0.93, 2.09) 1.20 (0.78, 1.86) 0.408 1.47 (1.04, 2.09) 1.41 (0.98, 2.05) 0.067
Sunshine hours/month* 0.99 (0.99, 0.99) 0.99 (0.99, 0.99) <0.001 0.99 (0.99, 0.99) 0.99 (0.99, 0.99) 0.001 0.99 (0.99, 0.99) 0.99 (0.99, 0.99) 0.001 0.99 (0.99, 0.99) 0.99 (0.99, 0.99) <0.001
HAQ (0–3) 0.86 (0.69, 1.07) 0.90 (0.71, 1.14) 0.384 – – – –
ACPA-positive – – 1.45 (1.00, 2.09) 1.45 (0.99, 2.12) 0.056 – – – –
HLA-B27 – – – – 0.68 (0.50, 0.92) 0.70 (0.48, 1.02) 0.062 – –
BASFI (0–10) – – – – 1.10 (1.02, 1.18) 1.08 (0.99, 1.17) 0.070 – –
Vitamin D therapy 0.60 (0.47, 0.77) 0.57 (0.43, 0.76) <0.001 0.69 (0.48, 0.99) 0.78 (0.52, 1.18) 0.245 0.46 (0.26, 0.81) 0.43 (0.26, 0.81) 0.008 0.48 (0.28, 0.82) 0.54 (0.29, 1.01) 0.053
*Hours of sunshine per month considering the period of time between 60 and 90 days prior to the baseline visit (blood test to determine the levels of 25(OH)D was performed at the baseline visit). 25(OH)D 25-
hydroxyvitamin D, OR odds ratio, BMI body mass index, HAQ (0–3): health assessment questionnaire, ACPA anti-cyclic citrullinated peptide antibodies, HLA-B27 histocompatibility antigen HLA-B27, BASFI (0–10) Bath
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high percentage of subjects with osteoarthritis and/or
osteoporosis, who are also likely to have low baseline 25
(OH)D levels.
Nowadays it is not clear whether vitamin D deficiency
is the cause or effect of the inflammatory process. In this
regard, in a model of acute phase response after surgery,
plasma concentrations of 25(OH)D were found to de-
crease after elective knee arthroplasty [32]. Furthermore,
several studies have found an inverse association between
25(OH)D levels and activity parameters of some CIRD,
such as DAS28, swollen joints and HAQ in RA and BASFI
and BASDAI in AS [17, 19, 21]. Although the results from
our study do not fully support all these findings, in the
multivariate analysis a marginally statistically significant
association between 25(OH)D deficiency and ACPA in
RA and BASFI in AS was found. It is worth noting that
our patients with CIRD had decreased 25(OH)D levels
despite the fact that a great majority had low activity at
the time of inclusion. Patients with CIRD have less mobil-
ity and life outdoors, which would also contribute nega-
tively to maintain adequate levels of vitamin D. Therefore,
25(OH)D deficiency in these patients may be explained by
a dual mechanism. On the one hand, chronic diseases can
predispose to 25(OH)D deficiency directly by decreasing
synthesis or increasing vitamin D catabolism, and on
the other hand, indirectly lowering sunlight exposure in
phases of reduced mobility and ability to spend time
outdoors in patients with worse functional status.
We feel that our results may be considered of potential
interest in daily clinical practice, as our population encom-
passed individuals periodically followed at rheumatology
outpatient clinics, many of whom are controlled under
biological treatment.
Although a recent umbrella review of systematic re-
views and meta-analyses of observational studies and
randomized trials did not demonstrate that supplemen-
tation of vitamin D improves the health of the general
population [33], we believe it is important to monitor
and supplement vitamin D to patients with CIRD and
vitamin D deficiency, regardless of whether the deficiency
of vitamin D may or may not have a pathogenic role, or
whether it is merely an epiphenomenon associated with
inflammatory disease.
Our study has some limitations. First, a potential limi-
tation of the study was that the non-CIRD subjects were
not completely healthy, as a high percentage of individuals
included had osteoarthritis, osteoporosis and/or other
musculoskeletal diseases, which by themselves are associ-
ated with some risk of 25(OH)D deficiency. Another
limitation of this study may be that the control group
had more sunshine hours because many controls were
recruited in the months of October and November, and
several studies indicate that the level of 25(OH)D is theresult of sun exposure in a period of time between 60
to 90 days prior to the 25(OH)D assessment [34], which
in our study corresponded with the months of July and
August. With respect to the variability of the vitamin D
measurement among all participating centers, we per-
formed a mixed model of logistic regression to reduce
the variability in the method of assessment of 25(OH)D
levels.
Finally, another limitation is the possible ecological
fallacy that we may be committing to impute the average
hours of sunshine from one province to every individual.
As the CARMA study was designed to determine the
causality of cardiovascular mortality in patients with
CIRD, information on the length of time during which
individual patients were exposed to sunshine was not
collected. Therefore, and because sun exposure is a key
factor in the blood levels of vitamin D, and patients were
not recruited in the same period of the year and in the
same geographical area of the country, we decided to
collect aggregate information on sunshine hours provided
by the SMA as an adjustment variable in the multivariate
model.
Conclusions
In summary, patients with RA followed at rheumatology
outpatient clinics have high risk of 25(OH)D deficiency,
in spite of presenting low-to-moderate disease activity due
to tight control of the disease. In consequence, we believe
that we must monitor the levels of vitamin D at baseline
and during follow up, and supplement vitamin D if any
deficiency is detected.
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